Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN-001 with Avelumab in Advanced Solid Tumors
NCT04601402Phase 1Completed
- Sponsor
- Genome & Company
- Start
- Oct 2020
- Primary completion
- Jan 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LR20011 in solid tumor, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 1 more, sponsored by Genome & Company. Primary endpoints: Incidence of Adverse Events at 1 year, Incidence of Laboratory abnormalities at 1 year and 2 more. Started Oct 2020; status: completed.
02
Drugs
LR20011
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04601402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601402.